Durcabtagene autoleucel治疗复发/难治多发性骨髓瘤的1期试验疗效与安全性
本研究为1期试验A部分,评估快速平台制备的BCMA CAR-T产品durcabtagene autoleucel在复发/难治多发性骨髓瘤患者中的安全性与疗效。55例患者全部成功制备,中位静脉到静脉时间24天,单次输注后总缓解率98%,严格完全缓解率55%,44例可评估患者中35例达MRD阴性。
要点
- 55例r/r MM患者全部成功制备,中位静脉到静脉时间24天。
- 总缓解率98%,严格完全缓解率55%,44例可评估中35例MRD阴性。
- 未出现非预期安全性事件,无迟发性神经毒性报告。
核心结论
- Durcabtagene autoleucel在r/r MM中显示高缓解率和可控安全性,支持进入2期试验。
研究设计与样本
- 1期研究A部分(NCT04318327),纳入55例复发/难治多发性骨髓瘤患者。
- 主要目标为安全性,次要目标包括缓解率、细胞动力学、免疫原性和制备可行性。
主要发现
- 55例患者全部成功制备,中位静脉到静脉时间24天。
- 单次输注后总缓解率98%,严格完全缓解率55%。
- 未出现非预期安全性事件,无迟发性神经毒性报告。
- 免疫表型和转录组分析证实终产品保留干样表型。
关键数值与推荐
- 单次输注四个扁平目标剂量之一:2.5×10^6至20×10^6 CAR T细胞。
临床怎么用
- 快速制备平台可缩短静脉到静脉时间至24天,提高患者可及性。
- 高ORR和MRD阴性率支持在重度经治侵袭性r/r MM中进一步开展2期试验(NCT05172596)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditional manufacturing of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabtagene autoleucel, a BCMA-directed CAR T cell therapy manufactured using a rapid platform aimed at preserving T cell stemness. Here, we present the primary findings of part A of a phase 1 study (NCT04318327) of durcabtagene autoleucel in patients with relapsed/refractory multiple myeloma (r/r MM). The primary objective was safety; secondary objectives included response rates, cellular kinetics, immunogenicity, and manufacturing feasibility. Durcabtagene autoleucel was successfully manufactured for all 55 patients (median vein-to-vein time, 24 days) and given as a single infusion at one of four flat target doses (2.5 × 106 to 20 × 106 CAR T cells). Among all patients, the overall response rate was 98%, and the stringent complete response rate was 55%. Eighty percent of evaluable patients (35 of 44) achieved minimal residual disease negativity. There were no unexpected safety findings and no reports of delayed neurotoxicity. Immunophenotyping and transcriptomic analyses confirmed preservation of a stem-like phenotype in the manufactured final product. On the basis of the safety, efficacy, and cellular expansion results from the phase 1 trial, a phase 2 trial (NCT05172596) was initiated to further explore the efficacy and safety of durcabtagene autoleucel in heavily pretreated patients with aggressive r/r MM.
引用
- Sperling AS, Derman BA, Nikiforow S, et al. Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026. PMID: 42202046. doi:10.1126/scitranslmed.adx1799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。